嗅素结构域家族蛋白3促进MYCN扩增型神经母细胞瘤细胞系体外增殖

doi:10.16352/j.issn.1001-6325.2025.02.0168

基础医学与临床 ›› 2025, Vol. 45 ›› Issue (2): 168-175.doi: 10.16352/j.issn.1001-6325.2025.02.0168

嗅素结构域家族蛋白3促进MYCN扩增型神经母细胞瘤细胞系体外增殖

张瑶, 张璇, 贾安娜, 战世佳, 郭金鑫, 常艳^*, 郭永丽^*

国家儿童医学中心首都医科大学附属北京儿童医院儿科重大疾病研究教育部重点实验室北京市儿科研究所儿童耳鼻咽喉头颈外科疾病北京市重点实验室, 北京 100045

收稿日期:2024-07-22 修回日期:2024-10-31 出版日期:2025-02-05 发布日期:2025-01-17
通讯作者: ^*guoyongli@bch.com.cn; changyan809@ccmu.edu.cn
基金资助:
北京市自然科学基金(7244341);国家自然科学基金(82141118,82172849)

Olfactory domain family protein 3 promotes the proliferation of MYCN-amplified neuroblastoma cell lines in vitro

ZHANG Yao, ZHANG Xuan, JIA Anna, ZHAN Shijia, GUO Jinxin, CHANG Yan^*, GUO Yongli^*

Beijing Key Laboratory for Pediatric Diseases of Otolaryngology, Head and Neck Surgery, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China

Received:2024-07-22 Revised:2024-10-31 Online:2025-02-05 Published:2025-01-17
Contact: ^*guoyongli@bch.com.cn; changyan809@ccmu.edu.cn

摘要/Abstract

摘要： 目的探究嗅素结构域家族蛋白3(OLFM3)在神经母细胞瘤(NB)中的功能。方法利用R2基因组分析及可视化平台分析OLFM3在NB临床样本中的表达水平和v-myc禽类骨髓细胞瘤病毒癌基因神经母细胞瘤衍生同源基因(MYCN)扩增和患儿预后之间的关系;分析Depmap数据库中OLFM3在不同肿瘤中的表达水平以及OLFM3表达与MYCN扩增的关系;在NB细胞系SK-N-BE(2)、SH-SY5Y和SK-N-AS中利用靶向siRNA干扰OLFM3的表达,RT-qPCR和Western blot检测OLFM3敲低水平;结晶紫染色和实时无标记细胞分析系统观察细胞增殖;克隆形成实验观察细胞克隆形成能力。结果 R2数据库分析发现MYCN扩增型NB肿瘤样本的OLFM3表达水平更高(P＜0.001);OLFM3高表达组患儿的总生存率明显低于低表达组(P＜0.05);Depmap数据库分析发现OLFM3在NB中表达水平较其他肿瘤高,MYCN扩增型细胞系中OLFM3的表达水平高于MYCN非扩增型细胞系(P＜0.01);在MYCN扩增型NB细胞中,OLFM3敲低后,细胞增殖能力(P＜0.001)和克隆形成能力显著下降(P＜0.001),但对MYCN非扩增型细胞无明显影响。结论 OLFM3特异性促进MYCN扩增型NB细胞增殖,但对MYCN非扩增型细胞影响较小,是MYCN扩增型高危NB的潜在生物标志物。

关键词: 神经母细胞瘤, v-myc禽类骨髓细胞瘤病毒癌基因神经母细胞瘤衍生同源基因扩增(MYCN), 嗅素结构域家族蛋白3, 细胞增殖

Abstract: Objective To explore the function of olfactomedin domain family protein 3 (OLFM3) in neuroblastoma (NB). Methods The relationship between the expression of OLFM3 mRNA and v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog(MYCN)amplification status and the prognosis of patients in NB clinical samples were clarified by using R2 Genomics Analysis and Visualization Platform. Depmap database was used to examine the expression level of OLFM3 in different tumors cell lines and to identify the correlation between OLFM3 expression and MYCN amplification status in various NB cell lines. RT-qPCR and Western blot were used to detect the knockdown level of OLFM3. Cell proliferation was monitored using crystal violet staining and real-time cellular analysis. The colony formation ability of NB cells was assessed using colony-forming unit assay. Results Analysis of R2 database revealed higher level of OLFM3 expression in MYCN-amplified NB clinical samples(P＜0.001). Patients with high OLFM3 expression showed a significantly lower overall survival probability compared to those with low OLFM3 expression(P＜0.05). Analysis with Depmap database revealed that the expression level of OLFM3 was higher in NB than that in other kind of tumor. The expression level of OLFM3 was significantly higher in the MYCN-amplified cell lines than in the MYCN-non-amplified cell lines(P＜0.01). In MYCN-amplified NB cells, knockdown of OLFM3 inhibited cells proliferation(P＜0.001) and colony formation(P＜0.001), but there was no noticeable changes observed in MYCN-non-amplified cells. Conclusions OLFM3 specifically promotes the proliferation of MYCN-amplified NB cells, but has a less effect on MYCN-non-amplified cells, indicating it is a potential biomarker for high-risk MYCN-amplified NB.

Key words: neuroblastoma, v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog(MYCN)amplification, olfactomedin domain family protein 3, cell proliferation

中图分类号:

R739.43

张瑶, 张璇, 贾安娜, 战世佳, 郭金鑫, 常艳, 郭永丽. 嗅素结构域家族蛋白3促进MYCN扩增型神经母细胞瘤细胞系体外增殖[J]. 基础医学与临床, 2025, 45(2): 168-175.

ZHANG Yao, ZHANG Xuan, JIA Anna, ZHAN Shijia, GUO Jinxin, CHANG Yan, GUO Yongli. Olfactory domain family protein 3 promotes the proliferation of MYCN-amplified neuroblastoma cell lines in vitro[J]. Basic & Clinical Medicine, 2025, 45(2): 168-175.

参考文献 15

[1]	Qiu B, Matthay K. Advancing therapy for neuroblastoma[J]. Nat Rev Clin Oncol, 2022, 19: 515-533.
[2]	Wolpaw AJ, Bayliss R, Büchel G, et al. Drugging the “undruggable” MYCN oncogenic transcription factor: overcoming previous obstacles to impact childhood cancers[J]. Cancer Res, 2021, 81: 1627-1632.
[3]	Tomarev SI, Nakaya N. Olfactomedin domain-containing proteins: possible mechanisms of action and functions in normal development and pathology[J]. Mol Neurobiol, 2009, 40: 122-138.
[4]	Tang S, Wang T, Zhang X, et al. Olfactomedin-3 enhances seizure activity by interacting with AMPA receptors in epilepsy models[J]. Front Cell Dev Biol, 2020, 8: 722, doi:10.3389/fcell.2020.00722.
[5]	Keenan J, Joyce H, Aherne S, et al. Olfactomedin Ⅲ expression contributes to anoikis-resistance in clonal variants of a human lung squamous carcinoma cell line[J]. Exp Cell Res, 2012, 318: 593-602.
[6]	贾安娜,战世佳,张璇等. C12ORF66对MYCN扩增的高危神经母细胞瘤细胞的活性调控[J]. 基础医学与临床, 2024, 44:288-294.
[7]	Volegova MP, Brown LE, Banerjee U, et al. The MYCN 5' UTR as a therapeutic target in neuroblastoma[J]. Cell Rep, 2024, 43: 114134, doi:10.1016/j.celrep.2024.114134.
[8]	Hagemann S, Misiak D, Bell JL, et al. IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression[J]. Mol Cancer, 2023, 22: 88, doi:10.1186/s12943-023-01792-0.
[9]	Dong Z, Yeo KS, Lopez G, et al. GAS7 Deficiency promotes metastasis in MYCN-driven neuroblastoma[J]. Cancer Res, 2021, 81: 2995-3007.
[10]	Zhou X, Wang X, Li N, et al. Therapy resistance in neuroblastoma: mechanisms and reversal strategies[J]. Front Pharmacol, 2023, 14: 1114295, doi:10.3389/fphar.2023.1114295.
[11]	Deng Z, Richardson DR, Insel P. The Myc family and the metastasis suppressor NDRG1: targeting key molecular interactions with innovative therapeutics[J]. Pharmacol Rev, 2023, 75: 1007-1035.
[12]	Lan MS, Chen C. Small molecules targeting INSM1 for the treatment of high-risk neuroblastoma[J]. Biology, 2023, 12: 1134, doi:10.3390/biology12081134.
[13]	Zafar A, Wang W, Liu G, et al. Targeting the p53-MDM2 pathway for neuroblastoma therapy: rays of hope[J]. Cancer Lett, 2021, 496: 16-29.
[14]	Li Z, Yang C, Li X, et al. The dual role of BI 2536, a small-molecule inhibitor that targets PLK1, in induction of apoptosis and attenuation of autophagy in neuroblastoma cells[J]. J Cancer, 2020, 11: 3274-3287.
[15]	Pham DC, Chang YC, Lin SR, et al. FAK and S6K1 inhibitor, Neferine, dually induces autophagy and apoptosis in human neuroblastoma cells[J]. Molecules, 2018, 23: 3110, doi:10.3390/molecules23123110.

编辑推荐 0

Metrics

阅读次数

全文

HTML			PDF

最新录用	在线预览	正式出版	最新录用	在线预览	正式出版
0	0	0	0	0	38

来源	本网站	其他网站

次数	37	1
比例	97%	3%

摘要

最新录用	在线预览	正式出版

0	0	73

	来源	本网站

	次数	73
	比例	100%

嗅素结构域家族蛋白3促进MYCN扩增型神经母细胞瘤细胞系体外增殖

Olfactory domain family protein 3 promotes the proliferation of MYCN-amplified neuroblastoma cell lines in vitro

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 15

相关文章 15

编辑推荐 0

Metrics

本文评价

[1]	姚安军, 陈凌子, 金惠仙. 二十二碳六烯酸抑制人结肠癌细胞系HT-29增殖[J]. 基础医学与临床, 2024, 44(8): 1107-1112.
[2]	曹清文, 祁琳, 禹博, 田晨晨, 袁海宁, 王越. 红景天苷促进人血管内皮细胞系EA.hy926增殖与迁移[J]. 基础医学与临床, 2024, 44(7): 925-930.
[3]	张鹏举, 李杰, 张梦迪, 孙少科, 许寅喆. KAT8通过增强METTL3表达促进结直肠癌细胞系增殖[J]. 基础医学与临床, 2024, 44(7): 931-939.
[4]	高寅洁, 童安莉. 醛固酮产生腺瘤中细胞死亡和增殖机制[J]. 基础医学与临床, 2024, 44(6): 758-762.
[5]	王婷婷, 萧宁, 林佃新, 董海涛. 大蒜素抑制口腔癌细胞系CAL27的增殖[J]. 基础医学与临床, 2024, 44(5): 673-676.
[6]	贾安娜, 郭金鑫, 张璇, 战世佳, 于永波, 郭永丽, 常艳. TMEFF1对神经母细胞瘤细胞系增殖的调控[J]. 基础医学与临床, 2024, 44(5): 637-644.
[7]	梁香存, 魏小雨, 梁健, 王庆, 耿广. 安罗替尼通过调控miR-16-5p/PD-1轴抑制人非小细胞肺癌细胞系增殖并促进凋亡[J]. 基础医学与临床, 2024, 44(4): 503-512.
[8]	陆凯, 陆建菊, 郭文利, 黄建棋, 李志华. lncRNA VIM-AS5在人乳腺癌细胞系中的表达及对乳腺癌细胞增殖和迁移的影响[J]. 基础医学与临床, 2024, 44(4): 447-453.
[9]	李娜, 李涛, 杨冬梨, 姚媛. 和厚朴酚抑制人脂肪间充质干细胞增殖[J]. 基础医学与临床, 2024, 44(4): 483-488.
[10]	贾安娜, 战世佳, 张璇, 郭金鑫, 于永波, 郭永丽, 常艳. C12ORF66对MYCN扩增的高危神经母细胞瘤细胞的活性调控[J]. 基础医学与临床, 2024, 44(3): 288-294.
[11]	廖镇城, 杨思懿, 吴平安. 提高m⁶A去甲基化酶FTO表达抑制鼻咽癌细胞增殖[J]. 基础医学与临床, 2024, 44(1): 57-62.
[12]	潘闪, 林铿强, 陈树兴. 培美曲塞抑制人肺腺癌细胞系A549增殖[J]. 基础医学与临床, 2023, 43(9): 1359-1363.
[13]	梁辉勇, 韦秋慧, 丁亚, 彭小青, 姚静, 苏齐鉴. 虫草素抑制TNF-α诱导的人角质形成细胞系HaCaT增殖[J]. 基础医学与临床, 2023, 43(9): 1390-1393.
[14]	张培波, 李义. 沙棘总黄酮抑制膀胱癌细胞系T24增殖[J]. 基础医学与临床, 2023, 43(7): 1122-1126.
[15]	侯孟杰, 赵娜, 黄富强, 王亚南, 刘芳铭. 载脂蛋白E通过降低高尔基体膜蛋白73表达抑制小鼠肝癌细胞系增殖[J]. 基础医学与临床, 2023, 43(5): 762-770.